Press "Enter" to skip to content

New patent for Astrazeneca Ab drug BYDUREON PEN

0
Copyright © DrugPatentWatch. Originally published at New patent for Astrazeneca Ab drug BYDUREON PEN

Annual Drug Patent Expirations for BYDUREON+PEN
Annual Drug Patent Expirations for BYDUREON+PEN

Bydureon Pen is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are twenty-two patents protecting this drug.

This drug has nineteen patent family members in fourteen countries.

The generic ingredient in BYDUREON PEN is exenatide synthetic. One supplier is listed for this compound. Additional details are available on the exenatide synthetic profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Astrazeneca Ab drug BYDUREON PEN
Online Certificate Course

Decision-Making for Generic Drug Entry & Branded Drug Lifecycle Management

  • When will key drug patents expire?
  • How can I find, evaluate, and plan for generic market entry opportunities?
  • How can I find proprietary out-of-court settlements and deal terms?
DrugPatentWatch - Make Better Decisions